300765 Cspc Innovation Pharmaceutical Co.,Ltd.
Closed 10-30 15:00:00
32.35
-2.63
-7.52%
High35.11Low32.35Vol20.46M
Open34.00D1 Closing34.98Amplitude7.89%
Mkt Cap45.45BTradable Cap45.45BTotal Shares1.41B
T/O684.00MT/O Rate1.46%Tradable Shares1.41B
P/B12.64ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

CSPC Innovation to Raise Related-Party Transactions' Estimated Amount in 2026; Shares Down 8%
MT Newswires Live  ·  10-29 14:41
CSPC Innovation to Raise Related-Party Transactions' Estimated Amount in 2026; Shares Down 8%
CSPC Innovation Pharma Logs Wider Q3 Attributable Loss; Revenue Up
MT Newswires Live  ·  10-29 14:35
CSPC Innovation Pharma Logs Wider Q3 Attributable Loss; Revenue Up
CSPC Pharmaceutical - 9M CSPC Innovation Pharma Cas Operating REV Rmb3.98 Bln
THOMSON REUTERS  ·  10-28
CSPC Pharmaceutical - 9M CSPC Innovation Pharma Cas Operating REV Rmb3.98 Bln
CSPC Pharmaceutical - CSPC Innovation Pharmaceutical 9M Net Profit Attributable RMB 1.21 Bln
THOMSON REUTERS  ·  10-28
CSPC Pharmaceutical - CSPC Innovation Pharmaceutical 9M Net Profit Attributable RMB 1.21 Bln
CSPC Innovation Pharmaceutical Subsidiary Presents Clinical Results of Two Drugs at Europe Cancer Congress
MT Newswires Live  ·  10-28
CSPC Innovation Pharmaceutical Subsidiary Presents Clinical Results of Two Drugs at Europe Cancer Congress
China Stocks Reverse Losses as State-Linked ETF Buying Picks Up
MT Newswires Live  ·  10-23
China Stocks Reverse Losses as State-Linked ETF Buying Picks Up
CSPC Innovation Pharmaceutical Unit Starts Breast Cancer Drug Trial
MT Newswires Live  ·  10-23
CSPC Innovation Pharmaceutical Unit Starts Breast Cancer Drug Trial
CSPC Innovation Pharmaceutical Wins China Nod for Solid Tumor Clinical Trial
MT Newswires Live  ·  10-16
CSPC Innovation Pharmaceutical Wins China Nod for Solid Tumor Clinical Trial
CSPC Innovation Pharmaceutical's Subsidiary SYS6002 Unveils Research Findings at 2026 IGCS Annual Global Meeting
Stock News  ·  10-08
CSPC Innovation Pharmaceutical's Subsidiary SYS6002 Unveils Research Findings at 2026 IGCS Annual Global Meeting
CSPC Innovation Pharmaceutical Gets Breakthrough Therapy Designation for Lung Cancer Investigational Drug
MT Newswires Live  ·  09-16
CSPC Innovation Pharmaceutical Gets Breakthrough Therapy Designation for Lung Cancer Investigational Drug
CSPC Innovation Pharmaceutical's SYS6010 Shows Promise in Lung Cancer Trial
MT Newswires Live  ·  09-15
CSPC Innovation Pharmaceutical's SYS6010 Shows Promise in Lung Cancer Trial
CSPC Innovation Pharma's SYS6010 Lands China's Breakthrough Therapy Product List
MT Newswires Live  ·  09-02
CSPC Innovation Pharma's SYS6010 Lands China's Breakthrough Therapy Product List
Cspc Innovation's Subsidiary Drug SYS6010 Granted Breakthrough Therapy Designation
Stock News  ·  09-01
Cspc Innovation's Subsidiary Drug SYS6010 Granted Breakthrough Therapy Designation
CSPC Innovation Pharmaceutical's Subsidiary Starts Phase I Trial of SYH2092 Injection
MT Newswires Live  ·  09-01
CSPC Innovation Pharmaceutical's Subsidiary Starts Phase I Trial of SYH2092 Injection
CSPC Innovation Pharmaceutical Subsidiary Gets China Clinical Trial Nod for Weight Loss Injection; Shares Fall 5%
MT Newswires Live  ·  08-28
CSPC Innovation Pharmaceutical Subsidiary Gets China Clinical Trial Nod for Weight Loss Injection; Shares Fall 5%
CSPC Innovation Pharma's Colorectal Cancer Drug Gets US FDA's Fast Track Designation; Shares Up 4%
MT Newswires Live  ·  08-27
CSPC Innovation Pharma's Colorectal Cancer Drug Gets US FDA's Fast Track Designation; Shares Up 4%
CSPC Innovation Pharmaceutical's Phase 3 Trial for Lung Cancer Drug Achieves Primary Endpoint of Progression-Free Survival
MT Newswires Live  ·  08-27
CSPC Innovation Pharmaceutical's Phase 3 Trial for Lung Cancer Drug Achieves Primary Endpoint of Progression-Free Survival
CSPC Innovation Pharma's Subsidiary Starts Trial for SYS6090 Injection
MT Newswires Live  ·  08-20
CSPC Innovation Pharma's Subsidiary Starts Trial for SYS6090 Injection
CSPC Innovation Subsidiary Initiates Phase Ib/II Clinical Trial for SYS6090
Stock News  ·  08-19
CSPC Innovation Subsidiary Initiates Phase Ib/II Clinical Trial for SYS6090
CSPC Innovation Posts RMB 1.26 Billion H1 Net Profit on RMB 3.24 Billion Revenue
Reuters  ·  08-17
CSPC Innovation Posts RMB 1.26 Billion H1 Net Profit on RMB 3.24 Billion Revenue

Introduction

Company Name.
石药创新制药股份有限公司
Industry:
食品制造业
Listing Date:
2019-03-22
Main Business:
　　石药创新制药股份有限公司的主营业务是生物制药、功能性原料及保健食品的研发、生产与商业化。公司的主要产品是抗体药物、ADC药物、mRNA疫苗、药品、咖啡因、阿卡波糖、无水葡萄糖原料及果维康维生素C含片、维生素B族含片。公司是国内首批实现mRNA疫苗产业化、ADC与抗体药物管线布局最完整的创新型生物药企业之一，已发展成为集源头创新、临床转化、规模生产与国际商业化于一体的高新技术企业。
Issue price:
24.47